{"id":3520,"date":"2015-11-25T19:53:04","date_gmt":"2015-11-25T19:53:04","guid":{"rendered":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?p=3520"},"modified":"2015-11-25T19:53:04","modified_gmt":"2015-11-25T19:53:04","slug":"intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom","status":"publish","type":"post","link":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/","title":{"rendered":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom"},"content":{"rendered":"<p>AMB 2015, 49, 81 Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom Zusammenfassung: Die Indikation f\u00fcr den Beginn einer medikament\u00f6sen Therapie zur Androgendeprivation (AD) bei Patienten mit Prostatakarzinom h\u00e4ngt vor allem ab von der Krankheitssituation, den vorhandenen Symptomen, der Vorbehandlung und dem Risikoprofil. Sie sollte gem\u00e4\u00df den aktuellen Leitlinien zur\u00fcckhaltend gestellt werden. Au\u00dferdem m\u00fcssen die Patienten [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AMB 2015, 49, 81 Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom Zusammenfassung: Die Indikation f\u00fcr den Beginn einer medikament\u00f6sen Therapie zur Androgendeprivation (AD) bei Patienten mit Prostatakarzinom h\u00e4ngt vor allem ab von der Krankheitssituation, den vorhandenen Symptomen, der Vorbehandlung und dem Risikoprofil. Sie sollte gem\u00e4\u00df den aktuellen Leitlinien zur\u00fcckhaltend gestellt werden. Au\u00dferdem m\u00fcssen die Patienten [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","footnotes":""},"categories":[1],"tags":[2190,2182,2180,2181,2191,56,638,2188,2189,2183,2185,2184,639,2186,2187,57,275,2192],"class_list":["post-3520","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-abirateron","tag-androgen-entzugstherapie","tag-androgene","tag-antiandrogene","tag-bicalutamid","tag-enzalutamid","tag-gnrh","tag-gnrh-agonisten","tag-gnrh-antagonisten","tag-gonadorelin","tag-gonadorelin-agonisten","tag-gonadorelin-antagonisten","tag-gonadotropin-releasing-hormon","tag-gonadotropin-releasing-hormon-agonisten","tag-gonadotropin-releasing-hormon-antagonisten","tag-karzinome","tag-prostatakarzinom","tag-testosteron"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom<\/title>\n<meta name=\"description\" content=\"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom\" \/>\n<meta property=\"og:description\" content=\"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken --&gt;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/\" \/>\n<meta property=\"og:site_name\" content=\"Der Arzneimittelbrief\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/derarzneimittelbrief.de\" \/>\n<meta property=\"article:published_time\" content=\"2015-11-25T19:53:04+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg\" \/>\n<meta name=\"author\" content=\"Hiwot\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Hiwot\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/\"},\"author\":{\"name\":\"Hiwot\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"headline\":\"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom\",\"datePublished\":\"2015-11-25T19:53:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/\"},\"wordCount\":288,\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"keywords\":[\"Abirateron\",\"Androgen-Entzugstherapie\",\"Androgene\",\"Antiandrogene\",\"Bicalutamid\",\"Enzalutamid\",\"GnRH\",\"GnRH-Agonisten\",\"GnRH-Antagonisten\",\"Gonadorelin\",\"Gonadorelin-Agonisten\",\"Gonadorelin-Antagonisten\",\"Gonadotropin-Releasing-Hormon\",\"Gonadotropin-Releasing-Hormon-Agonisten\",\"Gonadotropin-Releasing-Hormon-Antagonisten\",\"Karzinome\",\"Prostatakarzinom\",\"Testosteron\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/\",\"name\":\"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"datePublished\":\"2015-11-25T19:53:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\"},\"description\":\"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/#primaryimage\",\"url\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\",\"contentUrl\":\"http:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/wp-content\\\/uploads\\\/2014\\\/01\\\/GPSP_Banner_AMB_01_2013.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#website\",\"url\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/\",\"name\":\"Der Arzneimittelbrief\",\"description\":\"Unabh\u00e4ngige Arzneimittelinformationen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.der-arzneimittelbrief.de\\\/nachrichten\\\/#\\\/schema\\\/person\\\/a430337ae39f7e856414023e2397b13c\",\"name\":\"Hiwot\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g\",\"caption\":\"Hiwot\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom","description":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/","og_locale":"de_DE","og_type":"article","og_title":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom","og_description":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","og_url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/","og_site_name":"Der Arzneimittelbrief","article_publisher":"http:\/\/www.facebook.com\/derarzneimittelbrief.de","article_published_time":"2015-11-25T19:53:04+00:00","og_image":[{"url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","type":"","width":"","height":""}],"author":"Hiwot","twitter_misc":{"Verfasst von":"Hiwot","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/#article","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/"},"author":{"name":"Hiwot","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"headline":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom","datePublished":"2015-11-25T19:53:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/"},"wordCount":288,"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","keywords":["Abirateron","Androgen-Entzugstherapie","Androgene","Antiandrogene","Bicalutamid","Enzalutamid","GnRH","GnRH-Agonisten","GnRH-Antagonisten","Gonadorelin","Gonadorelin-Agonisten","Gonadorelin-Antagonisten","Gonadotropin-Releasing-Hormon","Gonadotropin-Releasing-Hormon-Agonisten","Gonadotropin-Releasing-Hormon-Antagonisten","Karzinome","Prostatakarzinom","Testosteron"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/","name":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom","isPartOf":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/#primaryimage"},"image":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/#primaryimage"},"thumbnailUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","datePublished":"2015-11-25T19:53:04+00:00","author":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c"},"description":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom - UNABH\u00c4NGIGE ARZNEIMITTELINFORMATIONEN hier klicken -->","breadcrumb":{"@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/#primaryimage","url":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg","contentUrl":"http:\/\/www.der-arzneimittelbrief.de\/nachrichten\/wp-content\/uploads\/2014\/01\/GPSP_Banner_AMB_01_2013.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/intermittierende-versus-kontinuierliche-medikamentoese-androgendeprivation-bei-prostatakarzinom\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/"},{"@type":"ListItem","position":2,"name":"Intermittierende versus kontinuierliche medikament\u00f6se Androgendeprivation bei Prostatakarzinom"}]},{"@type":"WebSite","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#website","url":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/","name":"Der Arzneimittelbrief","description":"Unabh\u00e4ngige Arzneimittelinformationen","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/#\/schema\/person\/a430337ae39f7e856414023e2397b13c","name":"Hiwot","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4de5c07508f9b9a25fb2354c5c40a6bfb18ed47290c54c62a986b86e944e1dd1?s=96&d=mm&r=g","caption":"Hiwot"}}]}},"_links":{"self":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/comments?post=3520"}],"version-history":[{"count":3,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3520\/revisions"}],"predecessor-version":[{"id":3524,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/posts\/3520\/revisions\/3524"}],"wp:attachment":[{"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/media?parent=3520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/categories?post=3520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.der-arzneimittelbrief.de\/nachrichten\/api\/wp\/v2\/tags?post=3520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}